GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (NAS:ANAB) » Definitions » Cyclically Adjusted PS Ratio

AnaptysBio (AnaptysBio) Cyclically Adjusted PS Ratio : 16.29 (As of Jun. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is AnaptysBio Cyclically Adjusted PS Ratio?

As of today (2024-06-05), AnaptysBio's current share price is $24.27. AnaptysBio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.49. AnaptysBio's Cyclically Adjusted PS Ratio for today is 16.29.

The historical rank and industry rank for AnaptysBio's Cyclically Adjusted PS Ratio or its related term are showing as below:

ANAB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 13.34   Med: 15.86   Max: 17.84
Current: 15.94

During the past years, AnaptysBio's highest Cyclically Adjusted PS Ratio was 17.84. The lowest was 13.34. And the median was 15.86.

ANAB's Cyclically Adjusted PS Ratio is ranked worse than
78.97% of 504 companies
in the Biotechnology industry
Industry Median: 5.505 vs ANAB: 15.94

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AnaptysBio's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.268. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.49 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AnaptysBio Cyclically Adjusted PS Ratio Historical Data

The historical data trend for AnaptysBio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Cyclically Adjusted PS Ratio Chart

AnaptysBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 14.51

AnaptysBio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 14.51 15.13

Competitive Comparison of AnaptysBio's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, AnaptysBio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnaptysBio's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Cyclically Adjusted PS Ratio falls into.



AnaptysBio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AnaptysBio's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=24.27/1.49
=16.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AnaptysBio's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.268/131.7762*131.7762
=0.268

Current CPI (Mar. 2024) = 131.7762.

AnaptysBio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.066 100.428 0.087
201412 0.247 99.070 0.329
201503 0.041 99.621 0.054
201506 0.044 100.684 0.058
201509 0.303 100.392 0.398
201512 0.270 99.792 0.357
201603 0.325 100.470 0.426
201606 0.390 101.688 0.505
201609 0.214 101.861 0.277
201612 0.152 101.863 0.197
201703 0.000 102.862 0.000
201706 0.345 103.349 0.440
201709 0.000 104.136 0.000
201712 0.130 104.011 0.165
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.207 106.507 0.256
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.185 108.070 0.226
201909 0.000 108.329 0.000
201912 0.110 108.420 0.134
202003 0.550 108.902 0.666
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 2.194 109.897 2.631
202103 0.411 111.754 0.485
202106 1.096 114.631 1.260
202109 0.761 115.734 0.866
202112 0.037 117.630 0.041
202203 0.035 121.301 0.038
202206 0.043 125.017 0.045
202209 0.046 125.227 0.048
202212 0.239 125.222 0.252
202303 0.049 127.348 0.051
202306 0.130 128.729 0.133
202309 0.125 129.860 0.127
202312 0.339 129.419 0.345
202403 0.268 131.776 0.268

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AnaptysBio  (NAS:ANAB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AnaptysBio Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of AnaptysBio's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AnaptysBio (AnaptysBio) Business Description

Industry
Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonists. The entity generates revenue from collaborative research and development arrangements.
Executives
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Eric J Loumeau officer: General Counsel C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Daniel Faga director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Dennis Mulroy officer: Chief Financial Officer
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Hamza Suria director, officer: President, CEO C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
J. Anthony Ware director C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Marco Londei officer: Chief Medical Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Dominic Piscitelli officer: Chief Financial Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
James N Topper director 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301